Clinical trials: Cushings Disease
Cushing Disease
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma.
- Trial name
- NCT00171951
- Testing
- Pasireotide
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Cushings Disease
Treatment of Cushing's Disease With R-roscovitine
The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease.
- Trial name
- NCT02160730
- Testing
- R-roscovitine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shlomo Melmed, MD
Cushing Disease
Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
Automated immunodosage methods (Roche Elecsys cortisol and IDS cortisol dosing kits) offer a simple and inexpensive technology routinely used in a medical biology laboratory.
- Trial name
- COSHING (NCT03974789)
- Testing
- Blood test, 24-hour Urine test, Saliva swab
- Where
- France
- Volunteers
- 380 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cushing Disease
The Factors Associated With the Recurrence in Patients With Cushing Disease
Cushing syndrome refers the manifestations induced by chronic glucocorticoid excess and may arise from various causes. Iatrogenic Cushing syndrome accounts for most patients, when they are given exogenous glucocorticoid…
- Trial name
- NCT02233335
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- National Taiwan University Hospital
Cushing's Disease
Long-term Cardiovascular Risk in Cured Cushing's Patients
The purpose of this study is to determine whether subjects who have been affected by Cushing's disease in the past maintain some different characteristics compared with subjects who have never been diagnosed with the disease.
- Trial name
- NCT00881283
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing's Disease
Mifepristone in Children With Refractory Cushing's Disease
Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease.
- Trial name
- NCT01925092
- Testing
- mifepristone
- Where
- United States
- Sponsor
- Corcept Therapeutics
Cushing's Disease
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol.
- Trial name
- BalanCeD (NCT06471829)
- Testing
- Lu AG13909
- Where
- 27 sites in United States, France and 7 more
- Volunteers
- 16 people
- Sponsor
- H. Lundbeck A/S
Cushing Disease, ACTH-producing Pituitary Tumour
Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs).
- Trial name
- PiTFET (NCT07463625)
- Testing
- Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Cushing Disease
Hair Cortisol and Cushing's Disease
The biochemical tools usable to assess the control of hypercortisolism in patients with Cushing's disease receiving medical treatments are debatable.
- Trial name
- HAIRCUSH (NCT04201444)
- Testing
- Patient group, Remission control group, Bilateral surrenalectomy control group
- Where
- 7 sites in France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Bordeaux
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Iatrogenic Cushing Disease
Prevention of Metabolic Complications of Glucocorticoid Excess
According to current estimates, nearly 1% of the general population is treated with long-term glucocorticoids. Chronic hypercortisolism leads to a phenotype that resembles the metabolic syndrome.
- Trial name
- NCT01319994
- Testing
- Metformin
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Barts & The London NHS Trust
Cushing's Disease, Cushing Syndrome
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes.
- Conditions
- Cushing's Disease, Cushing Syndrome, Cushing Disease
- Trial name
- NCT03364803
- Testing
- Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS)
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pituitary Neoplasm
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
Background: Cushing s disease can be caused by a tumor of the pituitary gland, a small gland about the size of a pea located at the base of the brain.
- Trial name
- NCT01459237
- Testing
- Acthrel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Cushing Disease
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease.
- Trial name
- NCT03774446
- Testing
- Seliciclib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cedars-Sinai Medical Center
Cushing Syndrome
The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
This is an observational, open, prospective multi-centre study designed to evaluate melatonin and cortisol circadian rhythm, immunological profile and anthropometric parameters in Cushing Syndrome patients during active Remission…
- Trial name
- TheHOURS (NCT03343470)
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Roma La Sapienza
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor.
- Conditions
- Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion
- Trial name
- RESCUE (NCT05307328)
- Testing
- SPI-62
- Where
- 12 sites in United States, Bulgaria and 1 more
- Volunteers
- 26 people
- Sponsor
- Sparrow Pharmaceuticals
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics